Abstract:Introduction Tacrolimus is a mainstay of immunosuppression after solid organ transplant to prevent organ rejection. While it has several well-established toxicities including kidney injury and central nervous system disturbances, its association with diffuse lung injury is rare. Case Description A 52-year-old man who underwent heart transplantation for genetic cardiomyopathy presented to the clinic three weeks post-transplant with subjective fever, night sweats, and exertional dyspnea. He was maintained on standard immunosuppression with tacrolimus, mycophenolate mofetil, and prednisone taper. Extensive workup for bacterial, viral, and fungal infections was unremarkable. Serial surveillance protocol right heart catheterizations showed normal filling pressures and hemodynamics, with no evidence of rejection on endomyocardial biopsies. CT chest, abdomen, and pelvis (Image A) at eight weeks since the first reported symptom onset was only notable for a new 5 mm lung nodule. The patient had gradually progressive dyspnea and hypoxia for which he underwent serial imaging. At twelve weeks, CT chest showed progression to multiple bilateral pleural-based lung nodules measuring up to 8mm. FDG-PET/CT (Image B) showed low-level activity and FDG uptake in some nodules concerning for malignancy or atypical infection. Given the peripheral location of the nodules, video-assisted thoracoscopic surgery and wedge resection was performed. Histopathology revealed nodules with abscess formation and fibrin deposits with no evidence of malignancy, granuloma, or infection. At six months, CT chest (Image C) revealed new diffuse bilateral ground glass opacities. Bronchoalveolar lavage showed no evidence of atypical microbial growth. After extensive discussions with pulmonology and infectious disease consultants, drug toxicity secondary to Tacrolimus was presumed to be the culprit. He was switched to Cyclosporine. After four weeks of Tacrolimus discontinuation, he had resolution of symptoms, and repeat imaging (Image D) demonstrated complete resolution of lung opacities with decreasing size of nodules. Tacrolimus was discontinued indefinitely. Conclusion Though described in case series in patients with rheumatoid arthritis, to the best of our knowledge, this is the first reported case of Tacrolimus-associated diffuse lung injury after a cardiac transplant. Extrapolating from data for rheumatoid arthritis, the lung injury is hypothesized to be a result of inflammatory cytokine-mediated endothelial injury. This could potentially explain the FDG uptake seen in our patient. Tacrolimus-associated diffuse lung injury, although rare, should be considered in patients who present with diffuse infiltrates, after appropriate workup to exclude other processes including malignancy and infection.

S4566 Tacrolimus-Induced Type IV Renal Tubular Acidosis in an Orthotopic, Cadaveric Liver Transplant Patient

Management of Tacrolimus-Induced Toxicity With Normal Serum Levels After Liver Transplant.

Distal tubular acidosis induced by FK506

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report

Acute pancreatitis due to tacrolimus in kidney transplant and review of the literature

Tacrolimus-Induced Diffuse Lung Injury

S2586 A Rare Case of Tacrolimus-Associated Acute Pancreatitis in a Liver Transplant Recipient

Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus

Tacrolimus-Induced Hepatic Vein Occlusive Disease After Deceased Donor Liver Transplantation: A Case Report

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Tacrolimus-Induced Recurrent Acute Coronary Syndrome Due to an Unknown Mechanism

The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease after Lung Transplantation: A Retrospective Analysis from a Single Transplantation Center.

Risk Factors for Standard Tac-related Nephrotoxicity in Renal Transplant Recipients

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

Hypertrophic cardiomyopathy secondary to tacrolimus therapy in a kidney transplant patient: A case report and focused review of the literature

New Onset Diabetic Ketoacidosis in a Renal Transplant Recipient

Effect of Jejunal Administration on Tacrolimus Trough Concentrations in a Pediatric Liver Transplant Recipient

Case Report: Acute Pancreatitis Associated With Tacrolimus in Kidney Transplantation and a Review of the Literature

The diagnosis and treatment of hy perk alemia caused by calcineurin inhibitor associated nephrotoxicity after liver transplantation

The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report